88 results
424B5
IMNM
Immunome, Inc.
14 May 24
Prospectus supplement for primary offering
8:48am
compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds … , business strategy, research and development costs, the anticipated timing, costs and conduct of our planned clinical trials for our product candidates
S-3ASR
IMNM
Immunome, Inc.
3 Apr 24
Automatic shelf registration
4:40pm
, our corporate strategy has shifted significantly. At the close of the Merger, Clay Siegall, Ph.D. became our President and Chief Executive Officer … our post-Merger strategy.
Zentalis Stock Issuance
On January 5, 2024, in connection with entering into the License Agreement, we entered into a stock
S-3ASR
d66mcv5f dicez
3 Apr 24
Automatic shelf registration
4:36pm
424B5
c87qman wh4bmy
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
n0fyk
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
h8egbxlz
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
rawij5y
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
q0k0h h84csf7m6ux4pc
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
1ytdbm
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
t2g7hx
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.1
81uj8uw014vxq
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.1
h1glnsi6zx6cb2l
15 Nov 23
Regulation FD Disclosure
6:03am